Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $9.03M rose 1733.8% year over year, ahead of the +350.1% change in trailing-twelve-month financing cash flow. Sequentially, it rose 62.8% from the prior quarter.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1733.8% holds above the trailing-twelve-month pace of +350.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.03M+62.8% QoQ
Last fiscal yearDec 2025
$12M+174.6% YoY
LTMMar 2026
$20.54M+350.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1733.8%——
1 year+174.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
12M USD
Year-over-year change
+174.6%
4-year CAGR
+43.4%

Financing Cash Flow vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +350.1% is the highest of 7, against a peer median of +52.4%.
GLSI Competitors
Financing Cash Flow for GLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMMXImmix Biopharma, Inc.LTM Mar 2026$107.35M USD—+221.5%—
IRDOpus Genetics, Inc.LTM Mar 2026$57.15M USD+156.6%+136.4%477.0%
SRZNSurrozen, Inc.LTM Mar 2026$38.95M USD-57.9%—519.7%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.04M USD+172.3%+87.5%—
AGENAgenus Inc.LTM Mar 2026$32.01M USD-71.3%+8.6%25.8%
HURATuHURA Biosciences, Inc.LTM Mar 2026$27.62M USD—+7.0%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$23.71M CAD+114.9%+16.7%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$20.54M USD+350.1%——
SEERSeer, Inc.LTM Mar 2026$11.67M USD-10.2%—77.6%
Peer median (excluding GLSI) —+52.4%+52.1%277.3%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.57M)(7.83M)(8.89M)(15.79M)(19.36M)
Depreciation & Amortization3.61K3.61K3.61K3.61K1.78K
Deferred Income Tax(1.19M)(1.75M)000
Stock-Based Compensation660.58K1.74M2.38M7.25M6.8M
Change in Working Capital(385.17K)(122.27K)31.5K1.27M2.64M
Accounts Receivables00000
Inventory00000
Accounts Payables(526.73K)035.47K921.22K2.07M
Other Working Capital141.57K(122.27K)(3.97K)344.11K568.12K
Other Non-Cash Items1.19M1.75M000
Operating Cash Flow(4.29M)(6.2M)(6.48M)(7.27M)(9.91M)
Capital Expenditures0(3)033
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued3.11M004.37M12M
Common Stock Repurchased0(7.54M)000
Dividends Paid00000
Other Financing Activities(275.15K)0000
Financing Cash Flow2.84M(7.54M)04.37M12M
Effect of Forex Changes00000
Net Change in Cash(1.46M)(13.74M)(6.48M)(2.9M)2.09M
Free Cash Flow(4.29M)(6.2M)(6.48M)(7.27M)(9.91M)

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.